Boehringer Ingelheim Pharmaceuticals, Inc.
B-294944.3,B-295430: Feb 2, 2005
Boehringer Ingelheim Pharmaceuticals, Inc. (BI) protests the terms of two solicitations issued by the Department of Veterans Affairs (VA) for Angiotensin II Receptor Antagonists, also known as Angiotensin II Receptor Blockers (or ARBs), for inclusion on the VA's National Formulary. One solicitation (request for proposals (RFP) No. RFP-797-NC-04-0016) seeks one of two identified ARBs for the treatment of patients with both hypertension and type 2 diabetes mellitus with nephropathy; the other (RFP No. RFP-797-NC-05-0003) seeks one of two identified ARBs for the treatment of patients with heart failure. BI, the manufacturer of an ARB not identified under either solicitation, argues that these solicitations are unduly restrictive because they exclude ARBs that treat simple hypertension, but do not treat the other conditions identified.
We deny the protests.